ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0212

Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks

Roy Fleischmann1, In-Ho Song2, Jeffrey Enejosa3, Eduardo Mysler4, Louis Bessette5, Patrick Durez6, Andrew Östör7, Jerzy Swierkot8, Yanna Song9 and Mark Genovese10, 1Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2AbbVie Inc., North Chicago, IL, 3AbbVie Inc., Evanston, IL, 4Organización Medica de Investigación, Buenos Aires, Argentina, 5Laval University, Quebec, Canada, 6Division of Rheumatology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium, 7Cabrini Medical Center, Monash University, Malvern, Victoria, Australia, 8Wroclaw Medical University, Wroclaw, Poland, 9AbbVie Inc., North Chicago,, IL, 10Stanford University Medical Center, Palo Alto, CA

Meeting: ACR Convergence 2020

Keywords: clinical trial, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: RA – Treatments Poster I: RA Treatments & Their Safety

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: We report safety/efficacy of upadacitinib (UPA) vs adalimumab (ADA) up to 72 weeks (wks) in patients (pts) with rheumatoid arthritis from the ongoing long-term extension (LTE) of SELECT-COMPARE.

Methods: Pts were randomized to once-daily UPA 15mg, placebo (PBO), or ADA 40mg every other wk. Pts were rescued at Wks 14/18/22 from UPA to ADA, ADA to UPA or PBO to UPA if they met protocol-specified rescue criteria; at Wk26 all remaining patients with CDAI >10 were rescued as above with all remaining PBO pts switched to UPA. Pts continued UPA or ADA in a blinded manner until the last pt completed the Wk48 visit. Completers entered the LTE. Treatment-emergent adverse events (TEAEs)/100PY were summarized up to December 26 2018. Efficacy was analyzed by randomized group. NRI was used for binary endpoints for rescue prior to Wk26.LOCF was used for continuous and binary endpoints for rescue at Wk26.

Results: 1629 pts were randomized (UPA: 1209 [399 non-switched; 159 switched from ADA; 651 from PBO]; ADA: 420 [168 non-switched; 252 switched from UPA]); 1403 entered the LTE. Cumulative exposures were 1396.7 and 515.1 PYs for UPA and ADA, respectively. TEAEs/100PY of any AEs and serious AEs for UPA vs ADA were 266.3 vs 299.4 and 12.7 vs 15.9, respectively. AE of special interest (AESIs)/100PY for UPA vs ADA were 3.7 vs 4.3 for serious infections, 0.9 vs 0.6 for opportunistic infections, 0.7 vs 1.0 for malignancy, 0.4 vs 0.6 for adjudicated MACE, 0.3 vs 1.0 for VTE, and 0.6 vs 1.2 for deaths. The event rates were numerically higher with UPA vs ADA for herpes zoster (3.1 vs 1.2), hepatic disorder (17.3 vs 14.0), and CPK elevation (5.6 vs 2.1). At Wk72, ACR20/50/70 was achieved by 64/51/38% vs 53/38/25% of pts on UPA and ADA (p< .01/.001/.001), DAS28-CRP≤3.2/< 2.6 by 49/41% vs 32/26% (p< .001), and CDAI≤10/≤2.8 by 46/28% vs 33/17% (p< .001), respectively.

Conclusion: UPA continued to demonstrate a safety profile consistent with observations through 48 wks and durable clinical efficacy.1

References:
                  1. Fleischmann R, et al. Annals of the Rheumatic Diseases 2019;78:744-745.
                      Original abs: Ann Rheum Dis. 2020; 79(S1):319.


Disclosure: R. Fleischmann, Pfizer, 2, 5; I. Song, AbbVie, 1, 3; J. Enejosa, AbbVie, 1, 3; E. Mysler, AbbVie, 2, 5, Amgen, 2, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Pfizer, 2, 5, Roche, 2, 5, Sandoz, 2, 5; L. Bessette, Amgen, 1, 2, 3, BMS, 1, 2, 3, Janssen, 1, 2, 3, UCB, 1, 2, 3, AbbVie, 1, 2, 3, Pfizer, 1, 2, 3, Merck, 1, 2, 3, Celgene, 1, 2, 3, Sanofi, 1, 2, 3, Lilly, 1, 2, 3, Novartis, 1, 2, 3, Gilead, 2, 6, 8; P. Durez, None; A. Östör, AbbVie, 5, Roche, 5, Janssen, 5, Eli Lilly, 5, Novartis, 5, Pfizer, 5, Gilead, 5, Paradigm, 5, UCB Pharma, 5, Bristol-Myers Squibb, 5; J. Swierkot, AbbVie, 2, 8, Sandoz, 2, 8, Pfizer, 2, 8, Roche, 2, 8, Bristol-Myers Squibb, 2, 8, UCB, 2, 8, MSD, 2, 8, Accord, 2, 8, Janssen, 2, 8; Y. Song, AbbVie, 1, 2; M. Genovese, Abbvie, 2, 5, Eli Lilly and Company, 2, 5, Galapagos, 2, 5, Gilead Sciences Inc., 2, 5, Pfizer, 2, 5, EMD Merck Serono, 2, 5, Genentech/Roche, 2, 5, GlaxoSmithKline, 2, 5, Novartis, 2, 5, RPharm, 2, 5, Sanofi-Genzyme, 2, UCB, 5, Amgen, 5.

To cite this abstract in AMA style:

Fleischmann R, Song I, Enejosa J, Mysler E, Bessette L, Durez P, Östör A, Swierkot J, Song Y, Genovese M. Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/long-term-safety-and-effectiveness-of-upadacitinib-or-adalimumab-in-patients-with-rheumatoid-arthritis-results-at-72-weeks/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-safety-and-effectiveness-of-upadacitinib-or-adalimumab-in-patients-with-rheumatoid-arthritis-results-at-72-weeks/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology